Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically confirmed advanced and/or metastatic solid tumors which are not
amenable to standard therapy, with exceptions as defined in exclusion criteria

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Measurable disease according to RECIST criteria version 1.1

- Adequate bone marrow, cardiac, liver and renal function

Exclusion Criteria:

- Known or suspected central nervous system (CNS) metastases including leptomeningeal
metastasis; patients with radiologically stable, asymptomatic previously irradiated
lesion are eligible provided patients is >/= 4 weeks beyond completing cranial
irradiation and >/= 3 weeks of corticosteroid therapy

- Significant, uncontrolled concomitant diseases, including significant cardiovascular
or pulmonary disease

- Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy
for bone pain), any investigational agent or immunotherapy within 28 days of first
receipt of study drug

- Poorly controlled type 1 or type 2 diabetes

- Prior toxicities from chemotherapy or radiotherapy which have not regressed to Grade

- Known HIV, HBV and HCV infection

- Pulmonary embolism or any other thrombo-embolic event within 6 months prior to study
entry

- History of hematological malignancy within the last 5 years prior to study entry

- Patient requires high dose corticosteroid treatment ( i.e. > 20 mg dexamethasone a
day or equivalent for > 7 consecutive days)

- Pregnant or lactating women